These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Saquinavir and rifampicin for tuberculosis and AIDS: new considerations. Torres TS; Rolla VC Int J Tuberc Lung Dis; 2006 Nov; 10(11):1302; author reply 1302-3. PubMed ID: 17131794 [No Abstract] [Full Text] [Related]
6. [Treatment of pleural and pulmonary tuberculosis by drug combinations including rifampicin. Early results]. Cornudella R; Garcia-Besada JA; Castellano A Rev Clin Esp; 1972 Jul; 126(1):59-64. PubMed ID: 5080189 [No Abstract] [Full Text] [Related]
7. Status of drug resistance in tuberculosis after the introduction of rifampicin in India. Paramasivan CN J Indian Med Assoc; 2003 Mar; 101(3):154-6. PubMed ID: 14603961 [TBL] [Abstract][Full Text] [Related]
8. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. Cohen K; van Cutsem G; Boulle A; McIlleron H; Goemaere E; Smith PJ; Maartens G J Antimicrob Chemother; 2008 Feb; 61(2):389-93. PubMed ID: 18096560 [TBL] [Abstract][Full Text] [Related]
9. [Treatment of chronic tuberculosis patients with ethambutol and protoionamide combined with rifampicin and capreomicin]. Grassi C; Cornia G; Cirianni C; Garimoldi M; Ginesu F; Mandler F; Perna G; Pradella F G Ital Chemioter; 1968; 15(4):92-4. PubMed ID: 5744843 [No Abstract] [Full Text] [Related]
10. Rifampicin bioavailability: a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption. Ellard GA; Fourie PB Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S301-8; discussion S317-21. PubMed ID: 10593709 [TBL] [Abstract][Full Text] [Related]
11. Rifampicin desacetylation in the human organism. Maggi N; Furesz S; Pallanza R; Pelizza G Arzneimittelforschung; 1969 Apr; 19(4):651-4. PubMed ID: 5819167 [No Abstract] [Full Text] [Related]
13. Efforts of the WHO/IUATLD to solve the problem of poor bioavailability of rifampicin from FDC anti-tuberculosis products: is a change required in the direction of the approach in view of recent findings? Singh S Int J Tuberc Lung Dis; 2001 Sep; 5(9):880-2. PubMed ID: 11573905 [No Abstract] [Full Text] [Related]
14. [Maximum therapeutic efficiency of a guternary antitubercular preparation. (Streptomycin-ethambutol-rifampicin-isoniazid)]. Almansa de Cara S Rev Clin Esp; 1972 May; 125(4):353-6. PubMed ID: 5080180 [No Abstract] [Full Text] [Related]
15. Evaluation of FASTPlaqueTB-RIF for determination of rifampicin resistance in Mycobacterium tuberculosis complex isolates. Kisa O; Albay A; Bedir O; Baylan O; Doganci L Int J Tuberc Lung Dis; 2003 Mar; 7(3):284-8. PubMed ID: 12661845 [TBL] [Abstract][Full Text] [Related]
16. Pharmaceutical formulation of a fixed-dose anti-tuberculosis combination. Danckwerts MP; Ebrahim S; Pillay V Int J Tuberc Lung Dis; 2003 Mar; 7(3):289-97. PubMed ID: 12661846 [TBL] [Abstract][Full Text] [Related]
17. Anti-tuberculosis 4FDC tablets--mystery to chemistry. Dekker TG; Lötter AP Int J Tuberc Lung Dis; 2003 Mar; 7(3):205-6. PubMed ID: 12661831 [No Abstract] [Full Text] [Related]
18. Review of the Indian market of anti-tuberculosis drugs: focus on the utilisation of rifampicin-based products. Catalani E Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S289-91; discussion S317-21. PubMed ID: 10593707 [TBL] [Abstract][Full Text] [Related]